https://www.selleckchem.com/pr....oducts/nexturastat-a
Muscle invasive bladder cancer (MIBC) is an aggressive disease with high rates of local recurrence following radical cystectomy (RC). Currently, there are no clinically validated biomarkers to predict local only recurrence (LOR) and guide adjuvant treatment decisions. This pilot study evaluated the role of Ki-67, MRE11 and PD-L1 as predictive biomarkers for recurrence patterns in patients undergoing RC for MIBC. Our institutional cystectomy database containing cases from 1992-2014 was queried for patients with local only recurrenc
Like
Comment
Share
